Clinical

Articles

The latest episode of the ASTCT Talks episode features a discussion from Andrés Gómez De León, MD, and Perla Colunga, MD, on outpatient haploidentical stem cell transplantation.

Outpatient Haploidentical Stem Cell Transplantation

Zanubrutinib has been approved by the FDA for the treatment of patients with Waldenströms macroglobulinemia based on the results of the phase 3 ASPEN trial.

FDA Approves Zanubrutinib for the Treatment Waldenströms Macroglobulinemia

Patients with hematologic malignancies may be at a higher risk for breakthrough infections following full COVID-19 vaccination.

Risk of Breakthrough COVID-19 Infection May Be High in Population With Hematologic Malignancies

Priority review for a biologics license application for prophylactic abatacept has been granted by the FDA to help prevent the occurrence of severe graft-versus-host disease for patients undergoing hematopoietic stem cell transplant from an unrelated donor.

Priority Review for Abatacept BLA Granted by the FDA for GVHD Prophylaxis

Muhamed Baljevic, MD, considers the role of autologous stem cell transplantation for light chain amyloidosis in a peer perspective accompanying an article by Iuliana Vaxman, MD, and Angela Dispenzieri, MD.

Evolving Role of Autologous Stem Cell Transplantation for Light Chain Amyloidosis in the Modern Era

On this CancerNetwork® podcast, we examine the scientific evidence behind the National Comprehensive Cancer Network guidelines for hematologic malignancies.

Oncology Peer Review On-The-Go: Examining Evidence Underlying the NCCN Guidelines for Hematologic Malignancies

Videos

Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center, discusses novel treatment options for patients with hematologic malignancies at the 2021 American Society of Clinical Oncology Annual Meeting.

Julie Vose, MD, MBA, Discusses Novel Treatment Options for Hematologic Malignancies

Patients with hematologic malignancies and COVID-19 may experience a survival benefit after receiving convalescent plasma therapy.

Convalescent Plasma Therapy Linked to Potential Survival Benefit for Patients With Hematologic Cancers and COVID-19

Compared with a control therapy, ruxolitinib increased overall response and improved failure-free survival for patients with glucocorticoid-refractory or -dependent chronic graft-versus-host disease.

Ruxolitinib Improved Overall Response in the Treatment of Glucocorticoid-Refractory or -Dependent Chronic GVHD

The ROCK-2–targeting agent belumosudil is now approved by the FDA to treat adult and pediatric patients with chronic graft-versus-host disease after 2 prior lines of therapy.

Hematology | Topics